About SolveBio
SolveBio is a company based in New York (United States) founded in 2013 by David Gross was acquired by Quartz Bio in January 2023. SolveBio has raised $2 million across 3 funding rounds from investors including NIH, Quartz Bio and NIH SBIR/STTR. SolveBio operates in a competitive market with competitors including Helix, Benchling, Genuity Science, Inpharmatica and BioAge Labs, among others.
- Headquarter New York, United States
- Founders David Gross
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2 M (USD)
in 3 rounds
-
Latest Funding Round
$1.5 M (USD), Grant
Jan 08, 2018
-
Investors
NIH
& 6 more
-
Employee Count
Not available
-
Acquired by
Quartz Bio
(Jan 24, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of SolveBio
Unlock access to complete
Unlock access to complete
Funding Insights of SolveBio
SolveBio has successfully raised a total of $2M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $1.5 million completed in January 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in SolveBio
SolveBio has secured backing from 7 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include NIH, Quartz Bio and NIH SBIR/STTR.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Venture capital investments in technology sectors are handled by Andreessen Horowitz.
|
Locked | Locked | Locked | |
|
Early-stage investments are provided to transformative technology companies.
|
Locked | Locked | Locked |
Investor details for SolveBio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SolveBio
Investment portfolio details for SolveBio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - SolveBio
Detailed financials for SolveBio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Solvebio Comparisons
Peer comparison for SolveBio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of SolveBio
SolveBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Helix, Benchling, Genuity Science, Inpharmatica and BioAge Labs, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genomic database for clinical research is provided.
|
|
| Locked | Locked | Locked |
Cloud-based bioinformatics platform is offered for biotech research.
|
|
| Locked | Locked | Locked |
AI-based omics data analysis solutions are provided to researchers.
|
|
| Locked | Locked | Locked |
Developer of predictive informatics based platform for drug discovery
|
|
| Locked | Locked | Locked |
Bioinformatics platform is provided for biomarkers and drug discovery.
|
|
| Locked | Locked | Locked |
Genomic data is analyzed and interpreted via web-based applications.
|
Detailed competitors of SolveBio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Solvebio
Complete news archive for SolveBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SolveBio
SolveBio was founded in 2013 and raised its 1st funding round 1 year after it was founded.
SolveBio is headquartered in New York, United States. It is registered at New York, New York, United States.
SolveBio is a funded company, having raised a total of $2M across 3 funding rounds to date.
SolveBio was founded in 2013 in New York, United States, focusing on the biotechnology sector. Advanced data analytics for precision medicine are delivered across therapeutic development stages. Complex molecular data access is enabled without barriers, supporting translational and clinical teams in applying analytic tools, machine learning algorithms, and big data platforms for operational efficiency.
SolveBio's top competitors include Helix, Benchling and BioAge Labs.
SolveBio has 7 investors. Key investors include NIH, Quartz Bio, NIH SBIR/STTR, Max Levchin, and Andreessen Horowitz.